Skip to main content

Table 3 One-way sensitivity analysis and impact on remaining life years without treatment + net benefit from HAART for HIV patients in three CD4 strata.

From: Further benefits by early start of HIV treatment in low income countries: Survival estimates of early versus deferred antiretroviral therapy

 

Remaining life years without treatment + net benefit from HAART

Variable

CD4 <50

CD4 50-199

CD4 200-350

Base case

0.7 + 7.2

2.0 + 7.6

4.8 + 14.5

Low HIV-related mortality rate (HAART)

0.7 + 14.5

2.0 + 9.2

4.8 + 24.3

High HIV-related mortality rate (HAART)

0.7 + 4.4

2.0 + 6.4

4.8 + 8.5

High HIV-related mortality rate (no treatment)

0.9 + 7.0

2.1 + 7.4

5.2 + 13.9

Low HIV-related mortality rate (no treatment)

0.6 + 7.4

1.9 + 7.8

4.4 + 15.1

Start age 30

0.7 + 7.5

2.0 + 8.0

4.8 + 15.9

Start age 40

0.7 + 7.0

2.0 + 7.2

4.7 + 13.2

  1. Low and high values of mortality rates refer to upper and lower 95% CI of the combined weighted pooled estimates in table 1 and table 2.